CHARLOTTE, N.C., Oct. 30, 2024 (GLOBE NEWSWIRE) -- Prenetics, (NASDAQ: PRE) a leading health sciences company, announced today that management will participate in the Sidoti Virtual Micro Cap Conference being held on November 13-14, 2024.
Prenetics’ Chief Executive Officer Danny Yeung and Chief Financial Officer Stephen Lo will present virtually on Wednesday, November 13th at 8:30 a.m. ET. A link to the webcast can be accessed through the investor section of the Company’s website at https://ir.prenetics.com/.
Additionally, management will be available for one-on-one investor meetings on Wednesday, November 13th. To schedule a one-on-one meeting with Prenetics’ management, please contact your Sidoti representative or reach out to investor relations at PRE@mzgroup.us.
About Prenetics
Prenetics (NASDAQ:PRE), a leading health sciences company, is dedicated to advancing consumer and clinical health. Our consumer initiative is led by IM8, a new health and wellness brand and Europa, one of the largest sports distribution companies in the USA. Our clinical division is led by Insighta, our $200 million venture focused on multi-cancer early detection technologies. This is followed by ACT Genomics, which has achieved FDA clearance for comprehensive genomic profiling of solid tumors, and CircleDNA, which uses NGS to offer comprehensive DNA tests. Each of Prenetics’ units synergistically enhances our global impact on health, embodying our commitment to ‘enhancing life through science’. To learn more about Prenetics, please visit www.prenetics.com.
Investor Relations Contact:
investors@prenetics.com
PRE@mzgroup.us
Angela Cheung
Investor Relations / Corporate Finance
Prenetics Global Limited
angela.hm.cheung@prenetics.com
| Last Trade: | US$5.80 |
| Daily Change: | 0.80 16.00 |
| Daily Volume: | 45,931 |
| Market Cap: | US$61.670M |
March 05, 2025 February 11, 2025 January 21, 2025 December 19, 2024 | |
C4 Therapeutics is pioneering a new class of small-molecule drugs that selectively destroy disease-causing proteins via degradation using the innate machinery of the cell. This targeted protein degradation approach offers advantages over traditional drugs, including the potential to treat a wider range of diseases...
CLICK TO LEARN MORE
Compass Therapeutics is a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases. The company's scientific focus is on the relationship between angiogenesis, the immune system, and tumor growth...
CLICK TO LEARN MORE
